KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
Sclafani, Francesco (The Royal Marsden NHS Foundation Trust)
Chau, Ian (The Royal Marsden NHS Foundation Trust)
Cunningham, David (The Royal Marsden NHS Foundation Trust)
Hahne, Jens Claus (The Institute of Cancer Research)
Vlachogiannis, George (The Institute of Cancer Research)
Eltahir, Zakaria (The Royal Marsden NHS Foundation Trust)
Lampis, Andrea (The Institute of Cancer Research)
Braconi, Chiara (The Institute of Cancer Research)
Kalaitzaki, Eleftheria (The Royal Marsden NHS Foundation Trust)
De Castro, David Gonzalez (The Royal Marsden NHS Foundation Trust)
Wotherspoon, Andrew (The Royal Marsden NHS Foundation Trust)
Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron)
Glimelius, B (University of Uppsala)
Tarazona, Noelia (Universitat de València)
Begum, Ruwaida (The Royal Marsden NHS Foundation Trust)
Lote, Hazel (The Institute of Cancer Research)
Hulkki Wilson, Sanna (The Royal Marsden NHS Foundation Trust)
Mentrasti, Giulia (The Institute of Cancer Research)
Brown, Gina (The Royal Marsden NHS Foundation Trust)
Tait, Diana (The Royal Marsden NHS Foundation Trust)
Oates, Jacqueline (The Royal Marsden NHS Foundation Trust)
Valeri, Nicola (The Institute of Cancer Research)
Universitat Autònoma de Barcelona

Data:	2018
Resum:	There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples of 97 LARC patients who were treated with CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX ± cetuximab in a randomised phase II trial. KRAS mutation in G12D, G12V or G13D was detected in the ctDNA of 43% and 35% of patients with tumours that were mutant and wild-type for these hotspot mutations, respectively, according to standard PCR-based analyses on tissue. The detection rate in the ctDNA of 10 patients with less common mutations was 50%. In 26 cases ctDNA analysis revealed KRAS mutations that were not previously found in tissue. Twenty-two of these (84. 6%) were detected following repeat tissue testing by ddPCR. Overall, the ctDNA detection rate in the KRAS mutant population was 66%. Detection of KRAS mutation in ctDNA failed to predict prognosis or refine patient selection for cetuximab. While this study confirms the feasibility of ctDNA analysis in LARC and the high sensitivity of ddPCR, larger series are needed to better address the role of ctDNA as a prognostic or predictive tool in this setting.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Scientific reports, Vol. 8 (january 2018) , ISSN 2045-2322

DOI: 10.1038/s41598-018-19212-5
PMID: 29362371

9 p, 1.7 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats